Compare IZM & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZM | ICU |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 15.9M |
| IPO Year | 2023 | N/A |
| Metric | IZM | ICU |
|---|---|---|
| Price | $1.37 | $2.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 95.8K | ★ 141.1K |
| Earning Date | 10-24-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $187,048,691.00 | $881,000.00 |
| Revenue This Year | N/A | $691.85 |
| Revenue Next Year | N/A | $64.17 |
| P/E Ratio | $13.60 | ★ N/A |
| Revenue Growth | 5.12 | ★ 1195.59 |
| 52 Week Low | $0.87 | $2.20 |
| 52 Week High | $2.74 | $30.70 |
| Indicator | IZM | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 42.49 | 63.95 |
| Support Level | $1.30 | $2.26 |
| Resistance Level | $1.49 | $2.71 |
| Average True Range (ATR) | 0.21 | 0.23 |
| MACD | -0.07 | -0.05 |
| Stochastic Oscillator | 5.24 | 20.41 |
ICZOOM Group Inc. operates an e-commerce platform selling electronic components to SMEs in China across consumer electronics, IoT, automotive, and industrial control sectors. It offers two main product categories: semiconductor products, including integrated circuits and optoelectronics, and electronic equipment and tools such as electromechanical and MRO supplies. The company also provides services like customs clearance, temporary warehousing, and logistics, earning additional commission fees. The majority of its revenue comes from electronic component sales.
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.